secondary failure

sec·on·dar·y fail·ure

1. failure of the function of an organ as a result of antecedent pathology elsewhere;
2. decreasing responsiveness to a drug after an initial satisfactory response, usually occurring several months after initiation of treatment.

sec·on·dar·y fail·ure

(sekŏn-dar-ē fālyŭr)
1. Failure of function of an organ as a result of antecedent pathology elsewhere.
2. Decreasing responsiveness to a drug after an initial satisfactory response, usually occurring several months after initiation of treatment.
References in periodicals archive ?
These products offer a promising alternative mechanism of action for diabetes treatment and may be considered as an add-on therapy or if secondary failure occurs with other products.
It can be found that the number of secondary failure nodes has a significant reduction when the constraint condition of node bearing capacity is relaxed.
Ineffectiveness of an oral drug may be termed as primary failure (no history of response to the drug), secondary failure (lack of response after an initial period of euglycaemia), or non-response (this term is used for newer classes of drugs, in preference to 'failure').
Effect of the Gly972Arg, SNP43 and Prol2Ala polymorphisms of the genes IRS1, CAPN10 and PPARG2 on secondary failure to sulphonylurea and metformin in patients with type 2 diabetes in Yucatan, Mexico.
The failure of the firewalls separating different parts of the platform, a secondary failure since they were never designed to cope with an explosion, ignited the oil stores.
The failure of the firewalls separating different parts of the facility, a secondary failure since they were never designed to cope with an explosion, ignited the oil stores.
When circuit A is lost, the total load on circuit B is 16 amps, which will not cause a secondary failure.
She found that the character and distribution of skeletal effects was consistent with primary bone disease, but was more likely to be due to damage to embryonic sensory nerves arising in the neural crest, giving to secondary failure of bone and joint formation.
using algorithms to rebuild data), affecting performance and increasing the risk of a secondary failure or total loss of data.
The literature contains few data examining the results of therapy with second-generation sulfonylurea drugs in subjects with non-insulin-dependent diabetes mellitus (NIDDM) after the onset of secondary failure to first-generation agents.
Secondary failure mechanisms became apparent: spalling of concrete, offset joints, cracks from restrained joints, and the buildup of incompressible material in open, unsealed joints and cracks.
Novel classes of incretin mimetics, GLP-1 agonist and DDP-IV inhibitors, have the potential to improve time to secondary failure and are likely to be adopted by international guidelines in the near future.